tiprankstipranks
Advertisement
Advertisement

OKUR Stock Latest News

OnKure Maintained at Buy as Strategy Shifts to Next-Gen PI3Kα Inhibitors; $16 Price Target Reaffirmed
RatingsOnKure Maintained at Buy as Strategy Shifts to Next-Gen PI3Kα Inhibitors; $16 Price Target Reaffirmed
30m ago
OKUR
OnKure Shareholders Approve Amended 2024 Equity Incentive Plan
PremiumCompany Announcements
OnKure Shareholders Approve Amended 2024 Equity Incentive Plan
1M ago
8K
OKUR
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch
PremiumThe Fly
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch
2M ago
OKUR
OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target
PremiumRatings
OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target
2M ago
OKUR
OnKure Therapeutics files to sell 36.14M shares of Class A common for holders
PremiumThe Fly
OnKure Therapeutics files to sell 36.14M shares of Class A common for holders
3M ago
OKUR
OnKure Announces $150M Private Placement and Board Changes
PremiumCompany AnnouncementsOnKure Announces $150M Private Placement and Board Changes
4M ago
8K
OKUR
OnKure Therapeutics to sell 26.713M shares at $4.15 in private placement
Premium
The Fly
OnKure Therapeutics to sell 26.713M shares at $4.15 in private placement
4M ago
OKUR
OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
Premium
Ratings
OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
4M ago
OKUR
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
PremiumThe Fly
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
4M ago
OKUR
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
PremiumThe Fly
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
4M ago
OKUR
OnKure Therapeutics Advances Clinical Programs and Expands Focus
PremiumCompany Announcements
OnKure Therapeutics Advances Clinical Programs and Expands Focus
8M ago
OKUR
Promising Prospects for OnKure Therapeutics: Buy Rating Backed by OKI-219 Developments and Strategic Expansion
PremiumRatings
Promising Prospects for OnKure Therapeutics: Buy Rating Backed by OKI-219 Developments and Strategic Expansion
8M ago
OKUR
Strategic Delay and Diversification: OnKure Therapeutics Positioned for Growth with Buy Rating
PremiumRatingsStrategic Delay and Diversification: OnKure Therapeutics Positioned for Growth with Buy Rating
8M ago
OKUR
OnKure Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
Premium
Ratings
OnKure Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
8M ago
OKUR
OnKure Therapeutics files $200M mixed securities shelf
Premium
The Fly
OnKure Therapeutics files $200M mixed securities shelf
8M ago
OKUR
OnKure Therapeutics Announces Sales Agreement with Leerink
PremiumCompany Announcements
OnKure Therapeutics Announces Sales Agreement with Leerink
8M ago
8K
OKUR
OnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)
PremiumThe Fly
OnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)
8M ago
OKUR
Promising Developments in OnKure Therapeutics’ PI3Kα Mutant Breast Cancer Treatment: Analyst Recommends Buy Rating
PremiumRatings
Promising Developments in OnKure Therapeutics’ PI3Kα Mutant Breast Cancer Treatment: Analyst Recommends Buy Rating
9M ago
OKUR
VTI ETF News, 10/9/2025
PremiumMarket News
VTI ETF News, 10/9/2025
9M ago
LVO
VTI
VTI ETF News, 10/8/2025
PremiumMarket NewsVTI ETF News, 10/8/2025
9M ago
LVO
VTI
VTI ETF News, 10/7/2025
Premium
Market News
VTI ETF News, 10/7/2025
9M ago
VTI
BCAB
Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
Premium
Ratings
Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
10M ago
OKUR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >